Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment

• Published in: Frontiers in cellular neuroscience Vol. 16; p. 982760
• Main Authors: Bonanno, Silvia, Cavalcante, Paola, Salvi, Erika, Giagnorio, Eleonora, Malacarne, Claudia, Cattaneo, Marco, Andreetta, Francesca, Venerando, Anna, Pensato, Viviana, Gellera, Cinzia, Zanin, Riccardo, Arnoldi, Maria Teresa, Dosi, Claudia, Mantegazza, Renato, Masson, Riccardo, Maggi, Lorenzo, Marcuzzo, Stefania
• Format: Journal Article
• Language: English
• Published: Lausanne Frontiers Research Foundation 11.08.2022; Frontiers Media S.A
• Subjects: Adaptive immunity; Atrophy; biomarker; Cerebrospinal fluid; Cytokines; Disease; IL-1β; Immune system; Inflammation; Interleukin 10; Interleukin 22; Interleukin 23; Interleukin 4; Interleukin 6; Investigations; multisystemic; Mutation; Neuromuscular diseases; Neuroscience; nusinersen; Pathogenesis; Patients; Pediatrics; Phenotypes; SMA; SMN protein; Software; Spinal muscular atrophy; Tumor necrosis factor-TNF; Tumor necrosis factor-α; γ-Interferon; United States > US
• ISSN: 1662-5102; 1662-5102
• DOI: 10.3389/fncel.2022.982760

Background and Objectives - Multisystem involvement in SMA is gaining prominence since different therapeutic options are emerging making the way for new SMA phenotypes, and consequent challenges in clinical care. Defective immune organs have been found in preclinical models of SMA, suggesting an involvement of the immune system in the disease. However, the immune state in SMA patients has not been investigated so far. Here, we aimed to evaluate the innate and adaptive immunity pattern in spinal muscular atrophy (SMA) type 1 to type 3 patients, before and after nusinersen treatment. Methods – 21 pediatric SMA type 1, 2 and 3 patients and 12 adult SMA type 2 and 3 patients were included in this single-center retrospective study. A Bio-Plex ProTM Human Cytokine 13-plex Immunoassay was used to measure cytokines in serum and cerebrospinal fluid (CSF) of the study cohort before and after 6 months of nusinersen therapy. Results – We detected a significant increase in IL-1β, IL-4, IL-6, IL-10, IFN-γ, IL-17A, IL-22, IL-23, IL-31, IL-33, in serum of pediatric and adult SMA patients at baseline, compared to pediatric reference ranges and to adult healthy controls. Pediatric patients showed also a significant increase in TNF-α and IL-17F levels at baseline. IL-4, IFN-γ, Il-22, IL-23, and IL-33 decreased in serum of pediatric SMA patients after 6 months of therapy when compared to baseline. A significant decrease in IL-4, IL-6, INF-γ, and IL-17A was detected in serum of adult SMA patients after treatment. CSF of both pediatric and adult SMA patients displayed detectable levels of all cytokines with no significant differences after 6 months of treatment with nusinersen. Notably, a higher baseline expression of IL-23 in serum correlated with a worse motor function outcome after treatment in pediatric patients. Moreover, after six months of treatment, patients presenting a higher IL-10 concentration on serum showed a better Hammersmith Functional Motor Scale Expanded (HFMSE) score. Discussion – Pediatric and adult SMA patients show an inflammatory signature in serum that is reduced upon SMN2 modulating treatment, and the presence of inflammatory mediators in CSF. Our findings enhance SMA knowledge with potential clinical and therapeutic implications.